NCT01856933 (Clinical Trial / PSMA ADC)

Study Title
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) (NCT01856933)

Trial Description
The purpose of this study is to evaluate the effectiveness of Prostate Specific Membrane Antigen (PSMA ADC), as well as its safety and side effects for patients with advanced brain tumors. This study will also investigate how PSMA ADC metabolizes (breaks down).

This trial is sponsored by Progenics Pharmaceuticals. [1]

Study Data

  • Condition:
    • Glioblastoma Multiforme
    • Gliosarcoma
  • Interventions:
    • Drugs used in this trial
      • PSMA ADC
  • Phase: II
  • Enrollment: 6
  • Start: May 2013
  • Completion: February 2015
  • Last verified: June 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 13, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.